NPM1 and cancer: Additionally, low-throughput targeted microarray (154 cancer driver genes) has also proven beneficial for discovering novel IgG autoantibodies (against p53, NPM1, FGFR2, PIK3CA, GNA11, HIST1H3B, and TSC1) (sensitivity = 94.4%, specificity = 82.7%) and IgM autoantibodies (against TSHR, ERBB2, survivin, PIK3CA, and JAK2) (sensitivity = 39.1%, specificity = 95.18%) [30,36].